Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators

This article was originally published in The Pink Sheet Daily

Executive Summary

With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.

You may also be interested in...



Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.

Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.

Addex Extends Its Runway With CHF 20 Million Investment By BVF

Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.

Related Content

Topics

UsernamePublicRestriction

Register

PS070625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel